Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, Inc. (JAGX) has called a special stockholder meeting for October 23, 2026 to seek approval for several capital structure and financing actions. Key items include approval, under Nasdaq Listing Rule 5635(d), for issuing common stock upon exchange of 897.37 outstanding shares of Series Q Preferred Stock, which at an assumed $2.50 exchange price could result in up to 70,348,855 common shares (about 53.5% of post-exchange common shares).
Stockholders are also asked to approve repricing multiple warrant series covering 4,052 shares (plus related dividend and placement-agent shares, up to 49,690 shares total, about 8.7% of common stock) to an exercise price of $1.00, a reverse stock split at a ratio between 1‑for‑2 and 1‑for‑150, an increase in the 2014 Stock Incentive Plan reserve to 14% of fully diluted shares as of September 30, 2026, a lower floor price under an equity line with C/M Capital, and Nasdaq rule‑driven approval of share issuances to investor Joshua Mailman and his affiliates.
Jaguar Health, Inc. (symbol: JAGX) is the issuer of record for a Form 8-K filing submitted to the SEC.
Jaguar Health, Inc. (JAGX) is implementing a 1-for-15 reverse stock split of its issued and outstanding common stock, approved by stockholders at the April 2026 special meeting and authorized by its board of directors. The related Twelfth Amendment to the certificate of incorporation was filed in Delaware on September 14, 2026, and the split becomes effective at 12:01 a.m. Eastern Time on September 17, 2026.
At the effective time, every fifteen shares of common stock will be reclassified into one share, with no change to par value, and no change to the total number of authorized common or preferred shares. Outstanding stock options, warrants, and shares reserved under equity plans will be adjusted proportionately, and holders otherwise entitled to fractional shares will receive cash in lieu of fractions. Equiniti Trust Company, LLC will act as exchange agent, and trading will continue on The Nasdaq Capital Market under the symbol JAGX on a split-adjusted basis beginning September 17, 2026, with a new CUSIP of 47010C854.
Jaguar Health, Inc. (JAGX) reports that a special meeting of stockholders held on September 4, 2026 was called to order but could not proceed because there were not enough shares of voting common stock and Series Q Perpetual Preferred Stock present or represented by proxy to constitute a quorum.
No votes were taken on any of the proposals described in the definitive proxy statement filed August 3, 2026, and no business was conducted. The company states it will not adjourn or postpone this particular special meeting and it will not be reconvened, but it plans to evaluate whether to call a new special meeting in the future to consider the same, similar, or other proposals.
Jaguar Health, Inc. (JAGX) updates its at-the-market equity program, stating that the aggregate offering price of common stock it may sell under its Form S-3 ATM facility has been reduced to approximately $4.78 million pursuant to General Instruction I.B.6 of Form S-3.
The company calculates the aggregate market value of common stock held by non-affiliates at about $14.99 million, based on 5,335,075 non-affiliate shares at $2.81 per share as of July 6, 2026, and notes that approximately $214,660 of stock has been sold under the I.B.6 limits in the prior 12-month period. Ladenburg Thalmann remains the sole sales agent under the ATM Agreement, and JAGX common stock trades on Nasdaq at a last reported price of $0.7299 per share on September 2, 2026.
Jaguar Health, Inc. (symbol JAGX) has filed a prospectus covering the potential resale by two selling stockholders of up to 40,874,552 shares of voting common stock. This consists of 40,000,000 Purchase Shares that may be issued under a June 9, 2026 equity line of credit with C/M Capital Master Fund, LP and 874,552 Commitment Shares (including shares issuable from pre-funded warrants) issued as consideration for that agreement. Jaguar is not selling any shares in this offering and will receive no proceeds from stockholder resales, but may sell shares directly to C/M Capital under the Purchase Agreement for up to $40 million in aggregate gross proceeds at discounted prices tied to market VWAP, subject to conditions, a 4.99% Beneficial Ownership Limitation, and a 19.99% Nasdaq stockholder-approval cap already obtained. Shares outstanding were 4,910,402 as of July 10, 2026; if all registered shares were issued and outstanding, they would exceed 89.3% of that baseline, highlighting substantial potential dilution.
Jaguar Health, Inc. (JAGX) reported second quarter 2026 results and highlighted progress in its global development program for crofelemer targeting rare intestinal failure (IF) diseases. A key update was presentation of additional data at ESPGHAN 2026 on crofelemer as adjunctive oral therapy for pediatric IF, including ultrarare microvillus inclusion disease (MVID). The data showed a reduction of parenteral support normalized to body weight of up to 48% in a patient with MVID. Jaguar stated it expects the clinical package for a New Drug Application (NDA) for MVID to be ready by the end of 2026, with NDA submission planned for the second quarter of 2027.
Jaguar Health, Inc. (JAGX) reports markedly improved results for the six months ended June 30, 2026. Total revenue was $21.5 million, up from $5.2 million a year earlier, driven largely by a jump in license revenue to $19.1 million. Product revenue contributed $2.4 million.
Operating performance strengthened: the company recorded a net loss of $4.1 million, compared with a $21.2 million loss in the prior-year period. Operating cash flow turned positive at $3.5 million versus a $13.5 million outflow. Jaguar also reduced notes payable significantly, with total liabilities falling to $29.3 million from $57.0 million, and stockholders’ equity moving from a deficit of $18.7 million at December 31, 2025 to positive $4.9 million at June 30, 2026, aided by preferred stock and warrant transactions.
Jaguar Health, Inc. filed a notice that its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 will be filed late. The company cites delays in obtaining and compiling information, including significant and material subsequent event transactions, and states that these delays could not be resolved without unreasonable effort and expense.
Jaguar Health states that, in reliance on Rule 12b-25, it expects to file the Form 10-Q no later than the fifth calendar day following the prescribed due date. The company also cautions that previously unknown issues related to its financial statements or internal control over financial reporting could be identified and may lead to changes in anticipated results, potential delays beyond the permitted 5-day period, and possible volatility in its stock price.